Aldeyra Therapeutics Inc ALDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
-
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
-
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
-
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
-
Aldeyra Therapeutics Says Additional Trial Needed For FDA Approval of Dry-Eye Disease Treatment
-
Aldeyra Shares Continue to Rally After AbbVie Agrees to Licensing Option
-
Aldeyra Shares Rally After AbbVie Licensing Deal on Eye Drug
-
Aldeyra Therapeutics stock plunges on heavy volume after FDA finds 'substantive' issues with NDA for dry-eye disease treatment
Trading Information
- Previous Close Price
- $5.29
- Day Range
- $5.16–5.42
- 52-Week Range
- $1.42–6.55
- Bid/Ask
- $5.10 / $5.40
- Market Cap
- $314.93 Mil
- Volume/Avg
- 2,773 / 501,868
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.aldeyra.com
Comparables
Valuation
|
Metric
|
ALDX
|
VRDN
|
EXEL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 17.37 |
Price/Book Value | 3.20 | 4.70 | 3.57 |
Price/Sales | — | 4,598.90 | 4.05 |
Price/Cash Flow | — | — | 16.58 |
Price/Earnings
ALDX
VRDN
EXEL
Financial Strength
|
Metric
|
ALDX
|
VRDN
|
EXEL
|
|---|---|---|---|
Quick Ratio | 4.36 | 15.54 | 4.05 |
Current Ratio | 4.55 | 15.82 | 4.27 |
Interest Coverage | −21.22 | −92.88 | — |
Quick Ratio
ALDX
VRDN
EXEL
Profitability
|
Metric
|
ALDX
|
VRDN
|
EXEL
|
|---|---|---|---|
Return on Assets (Normalized) | −23.93% | −34.35% | 14.82% |
Return on Equity (Normalized) | −29.43% | −64.16% | 19.05% |
Return on Invested Capital (Normalized) | −29.82% | −41.62% | 14.99% |
Return on Assets
ALDX
VRDN
EXEL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Hjlvwrsgv | Gqsg | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dwymqzzn | Tdxwhy | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zbchsjqcv | Blggwy | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xqwzmxcws | Jwjzml | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Rmhvjyylz | Dtjw | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Rqppxtpq | Vfspy | $28.3 Bil | |||
| Moderna Inc
MRNA
| Xknbhtgp | Syc | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Qmbdwcxl | Mykn | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ccbctcwmz | Xyzzt | $13.3 Bil | |||
| Incyte Corp
INCY
| Yrhkvyhp | Jylbd | $13.0 Bil |
United States